Skip to content
Friday 17 July 2026EN · DE
City PM

European business, markets and politics

  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
Tuesday 16 June 2020 4:16 pm  |  Updated:  Tuesday 16 June 2020 4:27 pm

Government gives NHS immediate authorisation for coronavirus drug

By: Edward Thicknesse

Add as a preferred source on Google
anti-inflammatory drug, has been immediately approved to treat all UK hospitalised COVID-19 patients requiring oxygen, including those on ventilators, from today.

The government has given the NHS immediate authorisation to use the first drug shown to reduce the coronavirus death rate on patients.

Earlier today the results of a clinical trial carried out by Oxford University showed that dexamethasone, a common steroid, been proven to reduce the risk of death significantly in patients with severe forms of the disease.

The anti-inflammatory drug has now been approved to treat all UK hospitalised Covid-19 patients requiring oxygen, including those on ventilators, from today. 

The Recovery trial is the first anywhere in the world to show a treatment provides significant impact in reducing patient mortality.

In anticipation of a positive test result, the government had taken steps to stockpile the drug, meaning that there is already enough to treat over 200,000 people.

Health secretary Matt Hancock said that the new standard treatment would save thousands of lives.

He added: “Guided by the science, the UK is leading the way in the global fight against coronavirus – with the best clinical trials, the best vaccine development and the best immunology research in the world”.

The results of the trial showed that the drug reduced the death rate of those on ventilators from 41 per cent to 28 per cent, and of those requiring oxygen from 25 per cent to 20 per cent.

Based on the results, for every eight ventilated patients treated with the drug one life would be saved.

Likewise, one in every 25 patients requiring oxygen would be survive through the use of the drug alone.

England’s chief medical officer Chris Whitty said the findings were “the most important trial result” for the disease so far.

Read more

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus

Trending Articles

  • James Watt offers to buy back Brewdog

  • Citroën 2CV returns as a £13,000 electric car, and the timing is no accident

  • Motsepe backed to succeed Fifa’s Infantino by South African minister

  • Brewdog owner shrugs off James Watt takeover bid

  • Finsbury lines up Games Workshop splurge using merger windfall

More from City PM

  • Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

    Business Wire
  • Regulator wins decade-long pricing tussle with Pfizer

    Legal
    Hikma reported a jump in profit for 2024
  • Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

    Business Wire
  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

    Business Wire
  • City trader: ‘My coke dealer came to the Canary Wharf office every day at 9am’

    Video
    Skyline of Canada financial district with modern skyscrapers and historic landmarks under a clear blue sky
  • Starmer scrambles to make savings in bid to boost defence spending

    Politics
    Keir Starmer discussing UKs defense strategy with BAE Systems executives in a formal meeting setting
  • STOKR Secures CASP and PI Licences in Luxembourg Ahead of MiCAR Deadline

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy · Facebook